SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis

Pooling 10 large trials, SGLT2 inhibitors slowed kidney disease progression no matter how advanced the kidney disease or how little protein was in the urine, supporting their broad use.